Clinical Trials
15 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01649271 2025-02-11
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Boehringer Ingelheim
Phase 1 Completed
NCT00950742 2025-02-10
Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With HerceptinĀ® in Patients With HER2-positive Advanced Breast Cancer.
Boehringer Ingelheim
Phase 1 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02768337 2024-01-31
CamBMT1
Cambridge University Hospitals NHS Foundation Trust
Phase 1/2 Terminated
NCT02115048 2019-12-26
Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
Translational Research in Oncology
Phase 2 Terminated
NCT01125566 2019-07-18
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Boehringer Ingelheim
Phase 3 Completed
NCT01271725 2019-06-17
LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
Boehringer Ingelheim
Phase 2 Completed
NCT02511847 2016-04-15
Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib
National Taiwan University Hospital
Phase 2 Unknown
NCT01441596 2015-09-07
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Boehringer Ingelheim
Phase 2 Completed
NCT00431067 2014-06-09
Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Boehringer Ingelheim
Phase 2 Completed
NCT00425854 2013-12-31
An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00826267 2013-12-31
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Boehringer Ingelheim
Phase 2 Completed
NCT00708214 2013-12-30
BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT01531764 2013-10-18
BIBW 2992 (Afatinib) and Vinorelbine
University of Magdeburg
Phase 2 Terminated